Inhibitive effects of 131I labeling prostate stem cell antigen monoclonal antibody on prostate carcinoma cell line LNCap and PC3

Abstract

Objective To investigate the inhibitive effects of 131Ⅰ labeling prostate stem cell antigen monoclonal antibody (131 Ⅰ-PSCA-McAb) on prostate carcinoma cell line LNCap and PC3 in vitro.Methods Prostate carcinoma LNCap cells and PC3 cells were cultured in vitro,and each cell line was divided into 4 groups:experimental group (adding 131Ⅰ-PSCA-McAb 2 g/L),monoclonal control group (adding PSCA-McAb 2 g/L),iodic control group (adding 131I 2 g/L),blank control group (adding saline solution 2 g/L).Cell inhibition of proliferation in each group was tested by methyl thiazol tetrazolium (MTF) assay; tumor apoptosis in each group was measured by flow cytometry; and invasiveness of cells was detected by Transwell invasion test.Results The inhibitory rates of LNCap experimental group and PC3 exerimental group reached (83.67 ± 2.52)％ and (80.33 ± 4.51)％,which obviously higher than monoclonal control groups [(73.33 ± 3.51)％ and (66.67 ± 5.03)％,P＜ 0.05] and iodic control groups [(53.33 ±4.51) ％ and (56.33 ± 2.52) ％,P ＜ 0.05].The apoptosis rates of LNCap experimental group and PC3 exerimental group reached (50.24 ±5.52)％ and (54.71 ±5.84)％ respectively,which obviously higher than monoclonal control groups [(42.23 ± 4.87)％ and (45.61 ± 5.60)％,P ＜0.05],iodic control groups [(26.75 ± 3.43) ％ and (22.26 ± 3.71) ％,P ＜ 0.05] and blank control groups [(14.18 ± 3.97) ％ and (15.14 ± 3.28) ％,P ＜ 0.05].The number of cells invading the membrane in LNCap experimental group and PC3 exerimental group was 33.34 ± 5.82 and 34.91 ± 6.10 respectively,which obviously less than monoclonal control groups (89.15 ± 7.96 and 92.04 ± 8.44,P ＜0.05),iodic control groups (97.83 ± 9.21 and 88.30 ± 8.12,P＜ 0.05) and blank control groups (119.04 ± 10.57 and 115.56 ± 11.08,P ＜ 0.05).Conclusion 131 Ⅰ-PSCA-mAb could effectively inhibit the growth and invasion ability of prostate carcinoma cell line LNCap and PC3,promote the apoptosis,and has the potential to become a new targeted therapy drug for the treatment of prostate carcinoma.131 Ⅰ-PSCA-McAb could effectively target PSCA and inhibit the growth of tumor,therefore was a promising radioimmunotherapy radiophamaceutical for prostate cancer. Key words: 131Ⅰ labeling prostate stem cell antigen monoclonal antibody; Cell proliferation; Cell apoptosis; Cell invasion; Radioimmunotherapy